Company intelligence / Profile preview

Mosaic Therapeutics

Cambridge, Cambridgeshire, United Kingdommosaic-tx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has in-licensed two clinical-stage oncology programs from Astex Pharmaceuticals: ASTX029 (ERK1/2 inhibitor that completed Phase 2) and ASTX295 (MDM2 antagonist that completed Phase 1). Each compound has been studied in more than 100 patients and demonstrated differentiated safety profiles and single-agent activity[4].

Therapeutic areas: Oncology
Modalities: Small moleculestargeted therapiescombination therapies
Industry: Biotech

Drug pipeline

5 assets

astx295

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Astex Pharmaceuticals

Beyond the preview

Go deeper on Mosaic Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mosaic Therapeutics.

Explore the full profile